RecruitingPhase 1NCT06665165
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
Studying Amyotrophic Lateral Sclerosis (ALS)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amylyx Pharmaceuticals Inc.
- Principal Investigator
- Medical Director, AmylyxMedical Monitor
- Intervention
- AMX0114(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (14)
- University of California, San Diego, La Jolla, California, United States
- Georgetown University Hospital Pasquerilla Healthcare Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Orlando Regional Medical Center, Orlando Health Neuroscience Institute, Orlando, Florida, United States
- Massachusetts General Hospital, Healey & AMG Center for ALS, Boston, Massachusetts, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Temple University of the Commonwealth System of Higher Education, Philadelphia, Pennsylvania, United States
- Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
- Houston Methodist Neurological Institute, Houston, Texas, United States
- University of Calgary, Calgary, Alberta, Canada
- McMaster University, Hamilton, Ontario, Canada
- London Health Sciences Centre, London, Ontario, Canada
- McGill University Health Centre - Centre for Innovative Medicine, Montreal, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06665165 on ClinicalTrials.govOther trials for Amyotrophic Lateral Sclerosis (ALS)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07017946Intestinal Microbiome Transplant in ALSDuke University
- ENROLLING BY INVITATIONNANCT07539662Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT07287397Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALSVector Y Therapeutics
- ACTIVE NOT RECRUITINGPHASE2NCT07023835Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral SclerosisZydus Therapeutics Inc.
- RECRUITINGNANCT07413718Inspiratory Muscle Training in Amiotrophyc Lateral SclerosisUniversity Ramon Llull
- RECRUITINGNANCT06609213Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALSAndrea Charvet
- RECRUITINGNANCT06249412The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS PatientsGroupe Hospitalier du Havre
- RECRUITINGNANCT06834269Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis.Campus Bio-Medico University